1. Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27:135–206
2. Katsaiti I, Nixon J (2018) Are there benefits in adding catechol-O-methyltransferase inhibitors in the pharmacotherapy of Parkinson’s disease patients. A systematic review. J Parkinsons Dis 8:217–231
3. Männistö PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson’s disease? Trends Pharmacol Sci 10:54–56
4. Männistö PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT). Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593–628
5. Tammimäki A, Aonurm-Helm A, Zhang F-P, Poutanen M, Garcia-Horsman JA, Duran-Torres G, Männistö PT (2016) Generation of MB-COMT deficient mice with distinct sex dependent behavioral phenotype. J Physiol Pharmacol 67:827–842